Abstract:Objective:To evaluate the efficacy and safety of Docetaxel/S-1/Oxaliplatin( DOS)and S-1/Oxali-platin( SOX)for the treatment of AGC. Methods:In a retrospective study,71 patients with AGC were analyzed. The patients were divided into two groups according to the regimen received:DOS group(36 cases)and SOX group(35 cases). In the DOS group,all patients received oral S-1 30mg/m2 ,twice daily,d1-14 . On d1 of every cycle,Oxalipla-tin 100mg/m2 was administered intravenously,and Docetaxel 60mg/m2 was administered. In the SOX group,all pa-tients received oral S-1 40mg/m2 ,twice daily,d1-14 . On d1 of every cycle,Oxaliplatin 130mg/m2 was administered intravenously,every 21 days. The efficacy and toxicity were evaluated after at least two consecutive courses. Results:All patients were evaluated for efficacy and safety. In the DOS group:CR 1 case(2. 8%),PR 16 cases(44. 4%),SD 10 cases(27. 8%),the response rate(RR)was 47. 2%,disease control rate(DCR)was 75%,and the median pro-gression free survival(PFS)time was 4. 4 months. In the SOX group:CR 0 case,PR 15 cases(42. 9%),SD 13 cases (37. 1%),the RR was 42. 9%,DCR was 80%,and the median PFS time was 4 months. The response rate,disease control rate and the median progression free survival were not significantly different between two groups(p>0. 05).Myelosuppression,gastrointestinal reaction,alopecia and sensory neuropathy were the most common adverse events ob-served in both groups. There were significantly more alopecia in the DOS group than in the SOX group(p<0. 001). There were significantly more sensory neuropathy in the SOX group than in the DOS group(p=0. 005). Conclusion:Both DOS and SOX are effective and well-tolerated for the treatment of advanced gastric cancer.

Docetaxel and Oxaliplatin plus S-1 versus S-1 plus Oxaliplatin for the treatment of ad-vanced gastric cancer(AGC)